Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT06819865
Recruiting Observational

A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

NCT06819865 · tracked via the Priya Life Science China tracker
Sponsor
Boston Scientific Corporation
Phase
Observational
Started
2026-09-30
Last updated
2026-10-26

Condition(s) studied

Acute Pulmonary Embolism

Investigational drug(s) / intervention(s)

EkoSonicTM Endovascular System

EkoSonicTM Endovascular System: EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).

Study summary

This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days). 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient. Exclusion Criteria: 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days). 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.

Primary outcome measure(s)

  • RV vs LV end-diastolic diameter ratio — after the completion of EKOS treatment 48 hours compared with the baseline
    The change in the right ventricular end-diastolic diameter to left ventricle end-diastolic diameter ratio at 48hours after the completion of EKOS treatment compared with the baseline.

Trial sites (1)

FacilityCityRegionStatus
The first Affiliated Hospital, Sun Yat-sen University Guangzhou Guangdong Recruiting

More Boston Scientific Corporation trials in China

IT Matters: The Erectile Restoration Registry Enrolling by invitation
FARAPULSE™ Pulsed Field Ablation System Active, not recruiting
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) Recruiting
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China Active, not recruiting
Intra-operative Pancreatoscopy in Patients With IPMN Active, not recruiting

Other trials for the same condition

The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism Active, not recruiting
Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06819865 on ClinicalTrials.gov ↗ ← All trials in China